Clinical Trials Logo

Clinical Trial Summary

To identify the efficiency of Irinotecan, Oxaliplatin, and S1 in patients with previously untreated local regional or metastatic pancreatic cancer.


Clinical Trial Description

This research study is a Phase 2 clinical trial. It will test the efficiency and safety of an investigational drug f Irinotecan,Oxaliplatin, and S1, with the goal of determining the OS of advanced pancreatic adenocarcinoma.. Subjects must have a newly diagnosed stage 4 untreated metastatic pancreatic ductal cancer and meet all inclusion/exclusion criteria. Treatment consists of treatment with Irinotecan 165mg/m2, Oxaliplatin 85mg/m2 on day 1, and S1 40mg orally on day 1-14, every 21 days each cycle. Treatment will be administered until untolerable toxicities or progression or subject death, or either the subject or sponsor discontinues the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03726021
Study type Interventional
Source Qingdao Central Hospital
Contact
Status Completed
Phase Phase 2
Start date January 26, 2018
Completion date February 28, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04025840 - Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery Phase 4
Completed NCT04111926 - Intraoperative Dexmedetomidine and Long-term Outcomes in Elderly After Major Surgery Phase 4
Recruiting NCT04101760 - Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03342300 - Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Phase 2/Phase 3
Recruiting NCT03910140 - TILA-TACE in Treatment of Hepatocellular Carcinoma N/A
Completed NCT03923400 - Jejunoileal vs Gastric GIST in the Era of Imatinib.
Withdrawn NCT02201381 - Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer Phase 3
Recruiting NCT05392257 - Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial Phase 2
Recruiting NCT05310370 - HRD and Resistance to PAPPi in EOC Patients
Recruiting NCT05310357 - Chromosomal Instability in Ovarian Cancer
Recruiting NCT05310305 - PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Active, not recruiting NCT04245644 - Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study
Recruiting NCT04245410 - Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma
Completed NCT02980185 - Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer N/A
Recruiting NCT03967457 - Comprehensive Study on the Quality of Life in Cervical Cancer Patients
Recruiting NCT04050787 - Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer N/A
Recruiting NCT03892577 - Real-world Study for Patients With Advanced Hepatobiliary Tumors
Not yet recruiting NCT02942238 - Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC) N/A
Not yet recruiting NCT01236989 - Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC N/A
Recruiting NCT05218629 - Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer Phase 2